These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26259716)

  • 1. Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach.
    Snoeys J; Beumont M; Monshouwer M; Ouwerkerk-Mahadevan S
    Clin Pharmacol Ther; 2016 Feb; 99(2):224-34. PubMed ID: 26259716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.
    Ouwerkerk-Mahadevan S; Snoeys J; Peeters M; Beumont-Mauviel M; Simion A
    Clin Pharmacokinet; 2016 Feb; 55(2):197-208. PubMed ID: 26353895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.
    Gertz M; Cartwright CM; Hobbs MJ; Kenworthy KE; Rowland M; Houston JB; Galetin A
    Pharm Res; 2013 Mar; 30(3):761-80. PubMed ID: 23179780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
    Treiber A; Schneiter R; Häusler S; Stieger B
    Drug Metab Dispos; 2007 Aug; 35(8):1400-7. PubMed ID: 17496208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically-based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B.
    Nakayama S; Toshimoto K; Yamazaki S; Snoeys J; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1461-1472. PubMed ID: 37667529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
    Brennan BJ; Moreira SA; Morcos PN; Navarro MT; Asthappan J; Goelzer P; Weigl P; Smith PF
    Clin Pharmacokinet; 2013 Sep; 52(9):805-13. PubMed ID: 23712757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
    Vavricka SR; Van Montfoort J; Ha HR; Meier PJ; Fattinger K
    Hepatology; 2002 Jul; 36(1):164-72. PubMed ID: 12085361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Drug-Drug Interaction Profile of Presatovir.
    Xin Y; Weng W; Murray BP; Eisenberg EJ; Chien JW; Ling J; Silverman JA
    J Clin Pharmacol; 2018 Jun; 58(6):771-780. PubMed ID: 29412463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
    Kudo T; Hisaka A; Sugiyama Y; Ito K
    Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
    Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
    Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling.
    Snoeys J; Beumont M; Monshouwer M; Ouwerkerk-Mahadevan S
    Clin Pharmacokinet; 2017 Jul; 56(7):781-792. PubMed ID: 27896690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.
    Varma MV; Lin J; Bi YA; Rotter CJ; Fahmi OA; Lam JL; El-Kattan AF; Goosen TC; Lai Y
    Drug Metab Dispos; 2013 May; 41(5):966-74. PubMed ID: 23393219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
    Kim SJ; Toshimoto K; Yao Y; Yoshikado T; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2715-2726. PubMed ID: 28479356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport.
    Kindla J; Müller F; Mieth M; Fromm MF; König J
    Drug Metab Dispos; 2011 Jun; 39(6):1047-53. PubMed ID: 21389119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
    Izumi S; Nozaki Y; Maeda K; Komori T; Takenaka O; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2015 Feb; 43(2):235-47. PubMed ID: 25414411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.
    Niemi M; Kivistö KT; Diczfalusy U; Bodin K; Bertilsson L; Fromm MF; Eichelbaum M
    Pharmacogenet Genomics; 2006 Aug; 16(8):565-8. PubMed ID: 16847425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling.
    Yao Y; Toshimoto K; Kim SJ; Yoshikado T; Sugiyama Y
    Drug Metab Dispos; 2018 Jul; 46(7):924-933. PubMed ID: 29712725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast.
    Varma MV; Kimoto E; Scialis R; Bi Y; Lin J; Eng H; Kalgutkar AS; El-Kattan AF; Rodrigues AD; Tremaine LM
    Clin Pharmacol Ther; 2017 Mar; 101(3):406-415. PubMed ID: 27648490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.